Given the pathogenic role of proinflammatory cytokines in AIRD-related atherosclerosis, tight control of disease activity with biologic DMARDs, including TNF-α inhibitors, IL-6 inhibitors, and IL-17 inhibitors, may reduce the risk of ASCVD [119,120,121]. This evidence concerns the gene IL17A and atherosclerosis.